Brokerages Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Target Price at $25.83

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have been assigned an average recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $25.83.

CNTA has been the subject of several analyst reports. TD Cowen started coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the transaction, the insider now owns 183,266 shares in the company, valued at approximately $3,236,477.56. This represents a 5.17 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CTO Tia L. Bush sold 17,813 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the transaction, the chief technology officer now directly owns 147,615 shares in the company, valued at $2,657,070. This trade represents a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,981 shares of company stock worth $7,814,333 over the last ninety days. Corporate insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after buying an additional 660 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares during the period. Atria Investments Inc grew its position in shares of Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after acquiring an additional 1,116 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $16.75 on Friday. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a fifty day simple moving average of $16.71 and a two-hundred day simple moving average of $15.79. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -10.95 and a beta of 1.53.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.